News
Current news
The Dual Role of Pho4 in the Environmental Stress Adaptation of Komagataella phaffii a l'estrès ambiental
30 07 2026
The study identifies two Pho4 transcription factors with complementary functions
New article: “Databases of liquid–liquid phase separation proteins and condensates”
28 07 2026
Research group: Protein Folding and Conformational Diseases
New article: “Peptideins: Navigating the gray zone of the proteome”
21 07 2026
Research group: Protein Folding and Conformational Diseases
IBB Secures Funding for Four Projects in the AEI call "Generación de Conocimiento 2025"
20 07 2026
The awards will support cutting-edge research in biomedicine, fertility, infectious diseases and diagnostic technologies, including two FPI predoctoral fellowships
New article: ““Too soon to tell”? The potential of tools like AggrescanAI for novel drug discovery and development”
14 07 2026
Research group: Protein Folding and Conformational Diseases
New article: “A pan-vertebrate signaling motif controls the molecular function of intracellular AQP12”
10 07 2026
Research group: Comparative Molecular Physiology
New article: “Can we vaccinate the brain? The promise of precision immunology”
09 07 2026
Research group: Protein Folding and Conformational Diseases
The IBB-UAB researcher Aura Muntasell wins the Vanguardia de la Ciència Award
07 07 2026
Aura Muntasell, IBB-UAB researcher, associate Professor in the Department of Cell Biology, Physiology and Immunology at the UAB and researcher at the Hospital del Mar Medical Research Institute (IMIM), has been awarded the Vanguardia de la Ciencia Award, which recognises the most outstanding research achievements led by Spanish research institutions. Her award-winning project focuses on the development of an innovative cancer immunotherapy strategy with the potential to improve the effectiveness of current treatments. The research received 25% of the public vote.
CAR therapies for neurodegeneration: a big challenge with increasingly plausible solutions
30 06 2026
The Protein Folding and Conformational Diseases research group, led by Salvador Ventura, defines the criteria that CAR immunotherapies for neurodegenerative diseases must meet to advance both conceptually and in trials, which are still at a very preliminary stage, in a review study published in the journal Trends in Pharmacological Sciences.
